67,214 Shares in Astrazeneca Plc $AZN Purchased by Park National Corp OH

Park National Corp OH bought a new stake in shares of Astrazeneca Plc (NYSE:AZN) in the third quarter, Holdings Channel.com reports. The institutional investor bought 67,214 shares of the company’s stock, valued at approximately $10,853,000.

Several other institutional investors and hedge funds have also bought and sold shares of AZN. Clal Insurance Enterprises Holdings Ltd grew its stake in Astrazeneca by 51.8% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 258 shares of the company’s stock worth $50,000 after buying an additional 88 shares during the last quarter. PFG Private Wealth Management LLC raised its stake in Astrazeneca by 5.5% in the second quarter. PFG Private Wealth Management LLC now owns 1,770 shares of the company’s stock valued at $336,000 after buying an additional 92 shares during the last quarter. Parrish Capital LLC boosted its holdings in Astrazeneca by 1.1% in the third quarter. Parrish Capital LLC now owns 9,792 shares of the company’s stock worth $1,581,000 after acquiring an additional 105 shares in the last quarter. Spinnaker Investment Group LLC grew its stake in shares of Astrazeneca by 3.8% during the second quarter. Spinnaker Investment Group LLC now owns 2,899 shares of the company’s stock worth $550,000 after acquiring an additional 106 shares during the last quarter. Finally, Syon Capital LLC increased its holdings in shares of Astrazeneca by 0.9% during the second quarter. Syon Capital LLC now owns 12,068 shares of the company’s stock valued at $2,288,000 after acquiring an additional 110 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Astrazeneca Stock Performance

Shares of AZN traded down $0.61 during trading hours on Monday, hitting $156.29. The stock had a trading volume of 984,018 shares, compared to its average volume of 2,797,352. The firm has a 50-day moving average price of $163.22 and a 200 day moving average price of $177.92. Astrazeneca Plc has a fifty-two week low of $153.41 and a fifty-two week high of $212.71. The firm has a market capitalization of $242.39 billion, a price-to-earnings ratio of 23.36, a PEG ratio of 1.32 and a beta of 0.27. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. The business had revenue of $15.38 billion during the quarter, compared to the consensus estimate of $15.44 billion. During the same quarter in the prior year, the firm posted $2.17 earnings per share. The company’s revenue was up 6.4% compared to the same quarter last year. As a group, research analysts anticipate that Astrazeneca Plc will post 9.37 EPS for the current year.

Wall Street Analyst Weigh In

AZN has been the topic of several research analyst reports. Zacks Research downgraded shares of Astrazeneca from a “hold” rating to a “strong sell” rating in a research report on Monday, September 14th. CICC Research started coverage on Astrazeneca in a research note on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 target price for the company. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Finally, Weiss Ratings lowered shares of Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, July 28th. Fourteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $206.67.

Astrazeneca Company Profile

AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, United Kingdom. Its research, development and commercial operations focus on prescription medicines for serious and chronic diseases, with an emphasis on discovering and delivering innovative therapies rather than operating as a diversified healthcare conglomerate.

The company’s principal therapeutic areas include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunological conditions; and rare diseases.